Search

Your search keyword '"Yiying Xiong"' showing total 2 results
Start Over Author "Yiying Xiong" Publisher public library of science (plos)
2 results on '"Yiying Xiong"'

1. Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation.

Author

Hua Jin, Yiying Xiong, Jing Sun, Yu Zhang, Fen Huang, Hongsheng Zhou, Zhiping Fan, Dan Xu, Yongqiang Wei, Min Dai, Ru Feng, and Qifa Liu

Subjects
Medicine, Science
Abstract

Imatinib can induce complete molecular remission (CMR) in relapse chronic myelogenous leukemia (CML) after allogeneic hematopoietic stem cell transplantation, but it is indefinite whether imatinib is required to maintain CMR. We retrospectively reviewed 37 relapse CML post-transplants treated with imatinib (n = 20) or donor lymphocyte infusion (DLI) (n = 17). The rate of CMR was 85% and 76.47% (P = 0.509) and treatment-related mortality was 0% and 29.4% (P = 0.019), respectively, in imatinib and DLI groups. Fifteen patients obtaining CMR voluntarily ceased imatinib, and did not experience relapse. The 8-year overall survival (OS) after relapse was 85%±8% and 40.3±12.1% (P = 0.017), and disease-free survival (DFS) after relapse was 85%±8% and 40.3±12.1% (P = 0.011), respectively, in imatinib and DLI groups. Imatinib resulted in higher OS and DFS than that of DLI in relapse CML. Imatinib maintenance might not be required for patients with relapse CML post-transplants after they achieved full donor chimerism and CMR.

Published
2013
Full Text
View/download PDF

2. Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation

Author

Hongsheng Zhou, Dan Xu, Yu Zhang, YiYing Xiong, Jing Sun, Ru Feng, Qifa Liu, Zhiping Fan, Fen Huang, Yongqiang Wei, Min Dai, and Hua Jin

Subjects
Male, Oncology, medicine.medical_treatment, lcsh:Medicine, Pilot Projects, Hematopoietic stem cell transplantation, Hematologic Cancers and Related Disorders, Recurrence, hemic and lymphatic diseases, Bone Marrow and Stem Cell Transplantation, Child, lcsh:Science, Multidisciplinary, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, Hematology, Middle Aged, Leukemia, Imatinib Mesylate, Medicine, Female, Research Article, medicine.drug, Adult, Drugs and Devices, medicine.medical_specialty, Adolescent, Immunology, Chronic Myeloid Leukemia, Antineoplastic Agents, Dermatology, Donor lymphocyte infusion, Young Adult, Myelogenous, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, Leukemias, medicine, Humans, Biology, neoplasms, Survival analysis, Retrospective Studies, Transplantation, Myeloproliferative Disorders, business.industry, lcsh:R, Cancers and Neoplasms, Imatinib, Immunologic Subspecialties, medicine.disease, Survival Analysis, Surgery, Clinical Immunology, lcsh:Q, business, Chronic myelogenous leukemia
Abstract

Imatinib can induce complete molecular remission (CMR) in relapse chronic myelogenous leukemia (CML) after allogeneic hematopoietic stem cell transplantation, but it is indefinite whether imatinib is required to maintain CMR. We retrospectively reviewed 37 relapse CML post-transplants treated with imatinib (n = 20) or donor lymphocyte infusion (DLI) (n = 17). The rate of CMR was 85% and 76.47% (P = 0.509) and treatment-related mortality was 0% and 29.4% (P = 0.019), respectively, in imatinib and DLI groups. Fifteen patients obtaining CMR voluntarily ceased imatinib, and did not experience relapse. The 8-year overall survival (OS) after relapse was 85%±8% and 40.3±12.1% (P = 0.017), and disease-free survival (DFS) after relapse was 85%±8% and 40.3±12.1% (P = 0.011), respectively, in imatinib and DLI groups. Imatinib resulted in higher OS and DFS than that of DLI in relapse CML. Imatinib maintenance might not be required for patients with relapse CML post-transplants after they achieved full donor chimerism and CMR.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results